Prybylski JP - Search Results

1

Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach.

Prybylski JP, Wang Y, Sahasrabudhe V, Purohit V. Prybylski JP, et al. AAPS J. 2024 Jun 6;26(4):65. doi: 10.1208/s12248-024-00928-4. AAPS J. 2024. PMID: 38844719

2

Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis.

Tsamandouras N, Qiu R, Hughes JH, Sweeney K, Prybylski JP, Banfield C, Nicholas T. Tsamandouras N, et al. Among authors: prybylski jp. J Pharmacokinet Pharmacodyn. 2024 Jun;51(3):265-277. doi: 10.1007/s10928-024-09901-2. Epub 2024 Mar 3. J Pharmacokinet Pharmacodyn. 2024. PMID: 38431923 Free PMC article. Clinical Trial.

3

Reporting Coefficient of Variation for Logit, Box-Cox and Other Non-log-normal Parameters.

Prybylski JP. Prybylski JP. Clin Pharmacokinet. 2024 Feb;63(2):133-135. doi: 10.1007/s40262-023-01343-2. Epub 2024 Feb 1. Clin Pharmacokinet. 2024. PMID: 38300488 No abstract available.

4

Influence of excess ligand on Nephrogenic Systemic Fibrosis associated with nonionic, linear gadolinium-based contrast agents.

Semelka RC, Prybylski JP, Ramalho M. Semelka RC, et al. Among authors: prybylski jp. Magn Reson Imaging. 2019 May;58:174-178. doi: 10.1016/j.mri.2018.11.015. Epub 2018 Nov 22. Magn Reson Imaging. 2019. PMID: 30471330

5

Impact of chelation timing on gadolinium deposition in rats after contrast administration.

Prybylski JP, Coste Sanchez C, Jay M. Prybylski JP, et al. Magn Reson Imaging. 2019 Jan;55:140-144. doi: 10.1016/j.mri.2018.10.006. Epub 2018 Oct 12. Magn Reson Imaging. 2019. PMID: 30321663 Free PMC article.

6

Scholarly publishing depends on peer reviewers.

Fernandez-Llimos F; Pharmacy Practice 2017 peer reviewers. Fernandez-Llimos F, et al. Pharm Pract (Granada). 2018 Jan-Mar;16(1):1236. doi: 10.18549/PharmPract.2018.01.1236. Epub 2018 Mar 27. Pharm Pract (Granada). 2018. PMID: 29619142 Free PMC article.

7

The Impact of Excess Ligand on the Retention of Nonionic, Linear Gadolinium-Based Contrast Agents in Patients With Various Levels of Renal Dysfunction: A Review and Simulation Analysis.

Prybylski JP, Jay M. Prybylski JP, et al. Adv Chronic Kidney Dis. 2017 May;24(3):176-182. doi: 10.1053/j.ackd.2017.03.002. Adv Chronic Kidney Dis. 2017. PMID: 28501081 Free PMC article. Review.

8

The stability of gadolinium-based contrast agents in human serum: A reanalysis of literature data and association with clinical outcomes.

Prybylski JP, Semelka RC, Jay M. Prybylski JP, et al. Magn Reson Imaging. 2017 May;38:145-151. doi: 10.1016/j.mri.2017.01.006. Epub 2017 Jan 10. Magn Reson Imaging. 2017. PMID: 28089499

9

Gadolinium deposition in the brain: Lessons learned from other metals known to cross the blood-brain barrier.

Prybylski JP, Maxwell E, Coste Sanchez C, Jay M. Prybylski JP, et al. Magn Reson Imaging. 2016 Dec;34(10):1366-1372. doi: 10.1016/j.mri.2016.08.018. Epub 2016 Aug 28. Magn Reson Imaging. 2016. PMID: 27580521 Review.

10

Can gadolinium be re-chelated in vivo? Considerations from decorporation therapy.

Prybylski JP, Semelka RC, Jay M. Prybylski JP, et al. Magn Reson Imaging. 2016 Dec;34(10):1391-1393. doi: 10.1016/j.mri.2016.08.001. Epub 2016 Aug 12. Magn Reson Imaging. 2016. PMID: 27530538 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12 results

Search Page